Efficacy, Systemic Safety, and Laboratory Outcomes of Low-Dose Atropine for the Prevention of Myopia Progression in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Primary Studies
Introduction: Myopia is the most prevalent refractive disorder of childhood, projected to approach 50% of the population by 2050. Low-dose atropine (0.01–0.05%) is the most investigated pharmacological intervention to slow myopia progression. Methods: A systematic review and meta-analysis was conducted per PRISMA 2020,...